S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)

IDEAYA Biosciences (IDYA) Stock Forecast, Price & News

$24.87
+0.95 (+3.97%)
(As of 06/2/2023 ET)
Compare
Today's Range
$23.57
$24.89
50-Day Range
$13.33
$23.92
52-Week Range
$9.00
$24.89
Volume
472,402 shs
Average Volume
561,301 shs
Market Capitalization
$1.42 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.40

IDEAYA Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
18.2% Upside
$29.40 Price Target
Short Interest
Bearish
9.13% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.59
Upright™ Environmental Score
News Sentiment
0.79mentions of IDEAYA Biosciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$21,436 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.02) to ($2.64) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

344th out of 983 stocks

Pharmaceutical Preparations Industry

160th out of 486 stocks


IDYA stock logo

About IDEAYA Biosciences (NASDAQ:IDYA) Stock

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Receive IDYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEAYA Biosciences and its competitors with MarketBeat's FREE daily newsletter.

IDYA Stock News Headlines

“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
Analyst Expectations for IDEAYA Biosciences's Future
“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
See More Headlines

IDYA Price History

IDYA Company Calendar

Last Earnings
5/09/2023
Today
6/02/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IDYA
Fax
N/A
Employees
81
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$29.40
High Stock Price Forecast
$40.00
Low Stock Price Forecast
$24.00
Forecasted Upside/Downside
+21.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Net Income
$-58,650,000.00
Net Margins
-143.90%
Pretax Margin
-143.90%

Debt

Sales & Book Value

Annual Sales
$50.93 million
Book Value
$5.83 per share

Miscellaneous

Free Float
54,368,000
Market Cap
$1.38 billion
Optionable
Not Optionable
Beta
0.84

Key Executives

  • Yujiro S. Hata
    President, Chief Executive Officer & Director
  • Andres Ruiz Briseno
    Head-Business Operations & Vice President
  • Paul A. StonePaul A. Stone
    Chief Financial Officer & Executive Vice President
  • Paul A. Barsanti
    Chief Technology Officer
  • Matthew Maurer
    VP, Head-Medical Affairs & Clinical Oncology













IDYA Stock - Frequently Asked Questions

Should I buy or sell IDEAYA Biosciences stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IDEAYA Biosciences in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IDYA shares.
View IDYA analyst ratings
or view top-rated stocks.

What is IDEAYA Biosciences' stock price forecast for 2023?

9 brokerages have issued 1-year price targets for IDEAYA Biosciences' shares. Their IDYA share price forecasts range from $24.00 to $40.00. On average, they anticipate the company's stock price to reach $29.40 in the next twelve months. This suggests a possible upside of 21.9% from the stock's current price.
View analysts price targets for IDYA
or view top-rated stocks among Wall Street analysts.

How have IDYA shares performed in 2023?

IDEAYA Biosciences' stock was trading at $18.17 on January 1st, 2023. Since then, IDYA shares have increased by 32.7% and is now trading at $24.11.
View the best growth stocks for 2023 here
.

When is IDEAYA Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our IDYA earnings forecast
.

How were IDEAYA Biosciences' earnings last quarter?

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) announced its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.49) earnings per share for the quarter, topping analysts' consensus estimates of ($0.52) by $0.03. The company had revenue of $7.90 million for the quarter, compared to analysts' expectations of $5.38 million. IDEAYA Biosciences had a negative net margin of 143.90% and a negative trailing twelve-month return on equity of 20.67%. The company's quarterly revenue was up 97.5% on a year-over-year basis.

What other stocks do shareholders of IDEAYA Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEAYA Biosciences investors own include Aldeyra Therapeutics (ALDX), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Boeing (BA), Xeris Biopharma (XERS), Entasis Therapeutics (ETTX), Livongo Health (LVGO) and NVIDIA (NVDA).

When did IDEAYA Biosciences IPO?

(IDYA) raised $70 million in an IPO on Thursday, May 23rd 2019. The company issued 5,000,000 shares at $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies acted as the underwriters for the IPO.

What is IDEAYA Biosciences' stock symbol?

IDEAYA Biosciences trades on the NASDAQ under the ticker symbol "IDYA."

Who are IDEAYA Biosciences' major shareholders?

IDEAYA Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Logos Global Management LP (7.44%), BlackRock Inc. (7.33%), BVF Inc. IL (4.29%), State Street Corp (3.69%), Price T Rowe Associates Inc. MD (3.03%) and Dimensional Fund Advisors LP (2.14%). Insiders that own company stock include Bvf Partners L P/Il, Jason Throne, Mark Lackner, Michael P Dillon, Michael P Dillon, Paul A Stone, Value Fund L P Biotechnology and Ventures Iv LP 5Am.
View institutional ownership trends
.

How do I buy shares of IDEAYA Biosciences?

Shares of IDYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IDEAYA Biosciences' stock price today?

One share of IDYA stock can currently be purchased for approximately $24.11.

How much money does IDEAYA Biosciences make?

IDEAYA Biosciences (NASDAQ:IDYA) has a market capitalization of $1.38 billion and generates $50.93 million in revenue each year. The company earns $-58,650,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis.

How can I contact IDEAYA Biosciences?

IDEAYA Biosciences' mailing address is 7000 SHORELINE COURT SUITE 350, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.ideayabio.com. The company can be reached via phone at (650) 443-6209 or via email at investor@ideayabio.com.

This page (NASDAQ:IDYA) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -